SLC5A2 and type 2 diabetes mellitus: In a meta‐analysis of 8 RCTs which compared combined therapy of SGLT2‐Is and ACEIs/ARBs with placebo plus ACEIs/ARBs in patients with type 2 diabetes, the combination therapy showed significant reduction in glycaemic parameters, body weight, blood pressure and lower risk of adverse events.21